Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos

A0220000

Aciclovir

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

Acycloguanosine, 9-[(2-Hydroxyethoxy)methyl]guanine, Acyclovir

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C8H11N5O3
Número CAS:
59277-89-3
Peso molecular:
225.20
Número MDL:
MFCD00057880
Código UNSPSC:
41116107
ID de substância PubChem:
329770584
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

acyclovir

fabricante/nome comercial

EDQM

aplicação(ões)

pharmaceutical (small molecule)

formato

neat

cadeia de caracteres SMILES

NC1=Nc2c(ncn2COCCO)C(=O)N1

InChI

1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15)

chave InChI

MKUXAQIIEYXACX-UHFFFAOYSA-N

Procurando produtos similares? Visita Guia de comparação de produtos

Categorias relacionadas

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Aciclovir EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

produto relacionado

Nº do produto
Descrição
Preços

1012065

Acyclovir, United States Pharmacopeia (USP) Reference Standard

1012076

Acyclovir Related Compound A, United States Pharmacopeia (USP) Reference Standard

Y0001264

Aciclovir for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001271

Aciclovir for peak identification 1, European Pharmacopoeia (EP) Reference Standard

1012087

Acyclovir Related Compound G, United States Pharmacopeia (USP) Reference Standard

1012054

Acyclovir Related Compound F, United States Pharmacopeia (USP) Reference Standard

BP438

Aciclovir, British Pharmacopoeia (BP) Reference Standard

Y0002245

Aciclovir for system suitability A, CRS, European Pharmacopoeia (EP) Reference Standard

Y0002244

Aciclovir for impurity G identification, European Pharmacopoeia (EP) Reference Standard

Y0002242

Aciclovir for impurity C identification, CRS, European Pharmacopoeia (EP) Reference Standard

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 2

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Choose from one of the most recent versions:

Certificados de análise (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Sonia Burrel et al.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 58(1), 321-324 (2013-06-05)
Herpes simplex virus type 1 (HSV-1) is a leading cause of corneal blindness. Acyclovir (ACV) constitutes the standard treatment of HSV infections including herpetic keratitis (HK). HSV resistance to ACV is mainly described in immunocompromised patients. We describe two cases
Monique van Velzen et al.
The Journal of infectious diseases, 208(9), 1359-1365 (2013-08-01)
Long-term acyclovir (ACV) prophylaxis, recommended to prevent recurrent herpes simplex virus type 1 (HSV-1) ocular disorders, may pose a risk for ACV-refractory disease due to ACV resistance. We determined the effect of ACV prophylaxis on the prevalence of corneal ACV-resistant
Adalbert Krawczyk et al.
Proceedings of the National Academy of Sciences of the United States of America, 110(17), 6760-6765 (2013-04-10)
Despite the availability of antiviral chemotherapy, herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) infections remain a severe global health problem. Of particular concern is the growing incidence of drug resistance in immunocompromised patients, which stresses the urgency
Swetha G Pinninti et al.
Pediatric clinics of North America, 60(2), 351-365 (2013-03-14)
Neonatal herpes simplex virus infections are uncommon, but because of the morbidity and mortality associated with the infection they are often considered in the differential diagnosis of ill neonates. The use of polymerase chain reaction for diagnosis of central nervous
Andrew Mujugira et al.
The Journal of infectious diseases, 208(9), 1366-1374 (2013-08-01)
Daily suppressive therapy with valacyclovir reduces risk of sexual transmission of herpes simplex virus type 2 (HSV-2) in HSV-2-serodiscordant heterosexual couples by 48%. Whether suppressive therapy reduces HSV-2 transmission from persons coinfected with HSV-2 and human immunodeficiency virus type 1
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica